US FDA’s Rx Drug Promo Study Answers $798,000 Question
Viewers spend more time on print ads that have more lengthy important safety information or a brief summary but impact on understanding is unclear, OPDP study finds. Another study finds exaggerated images of drug benefits in TV ads unsurprisingly can mislead consumers.
You may also be interested in...
US FDA study finds that sales aids for oncology drugs that disclose a study’s data limitations and clinical uncertainty can lead to more appropriate assessments of the data by physicians but does not affect their overall perceptions of a drug’s benefits.
US FDA staff acknowledge the challenge of assessing promotions on the internet as experts note trends and topics for future research, including the use of metadata and embedded advertisements, TikTok promotions, and DTC ads extending into countries that prohibit them.
US FDA will study how presentations of a fictitious cancer drug’s targeted mechanism of action affect consumer and provider interest in the drug and their understanding of its benefits and risks. Another study will assess how consumers and primary care physicians interpret Rx drug names.